Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Icahn Leaves Pool, Genzyme Shareholder No More

This article was originally published in The Pink Sheet Daily

Executive Summary

Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.

You may also be interested in...

Biogen Idec Clears The Air: No Large Companies Meet Dual Test For Acquisition

Putting a “permanent for sale sign out on the front lawn” is not the appropriate way to run the biotech either, CEO Mullen maintains.

Biogen Power Struggle: Icahn Seeks Board Seats

Billionaire investor Icahn asserts Biogen intentionally derailed a search for a buyer by refusing to allow interested parties to speak with its Tysabri partner, Elan.

Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007

Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts